PatientsVisitorsLocations & ServicesAbout the RegionJoin Our TeamPhysicians
Find:  Locations | Services
Pathology and Laboratory Medicine HomeTest and Services CatalogueTransfusion Medicine Product CataloguePolicy and ProcedureJob AidsSpecimen Collection and TransportRequisitionsAntibiogramsGenetic Testing and Molecular GeneticsMicrobiology EssentialsTransfusion EssentialsReference RangesLaboratory SuppliesAcute Care SCM GuidelinesContact InformationPhysician Access to Patient ResultsOpening A New Clinic
Pathology and Laboratory Medicine
Transfusion Essentials

​Special Requirements for Blood Products


​Special Requirement
​Eligible Patients
Irradiated  Cellular Blood Components
  • ​Low birth weight premature newborns ( less than 1200 g) until 4 months of age
  • History of intrauterine transfusion, until 6 months after the initial expected delivery date (40 weeks gestational age)
  • Neonatal exchange transfusion
  • Directed donations
  • HLA matched components
  • Allogenic stem cell/bone marrow transplant recipients (from start of conditioning chemotherapy, for life after transplant)
  • Autologous stem cell/bone marrow transplant recipients (from 7 days before the start of stem cell mobilization, until 6 months post-transplant)
  • Allogeneic stem cell donors (7 days prior to collection and during the collection process only)
  • Congenital T-cell immune deficiency (DiGeorge syndrome, SCID)
  • Hodgkin’s Lymphoma, for life
  • Patients receiving or who have received the following (for life, from the time of drug initiation):
    • Anti-thymocyte globulin (ATG; Thymoglobulin, Atgam)
      • If given for severe aplastic anemia or conditioning prior to allogeneic bone marrow transplant
    • Alemtuzumab (Campath, Lemtrada)
    • Bendamustine (Treakisym, ribomustin, Levact and Treanda)
    • Cladribine/2-CDA (Leustatin)
    • Clofarabine (Clolar)
    • Deoxycoformicin/Pentostatin
    • Fludarabine (Fludara)
CMV Negative Cellular Blood Components
  • ​Intrauterine transfusion (not available in Saskatchewan)

All blood components in Canada have undergone pre-storage leukoreduction and are considered “CMV safe”. Transfusion of leukoreduced plus CMV seronegative blood components has not been identified to provide additional protection against transfusion-transmitted CMV. 

Apheresis platelets
  • ​Aplastic anemia
  • Congenital marrow failure disorders (Diamond Blackfan anemia, Fanconi anemia)
  • Pediatric patients requiring less than 200 mL
  • Neonates (less than 4 months old)
  • Patients meeting requirements for HLA or HPA Matched platelets (see below)
HLA Matched Apheresis Platelets
  • Patients with HLA antibodies and demonstrated platelet refractoriness
HPA Matched Apheresis Platelets
  • Patients with HPA1a (PLA1) antibodies
  • Neonates with Neonatal Alloimmune Thrombocytopenia (NAIT)
  • Patients with history of Post Transfusion Purpura (PTP)
Phenotype Matched Red Blood Cells for Rh and Kell (prophylactic antigen matching as per local policy)
  • ​Aplastic anemia, pure red cell aplasia
  • Congenital marrow failure disorders (Diamond Blackfan anemia, Fanconi anemia)
  • Sickle cell anemia
  • Thalassemia
Washed Red Blood Cells
  • ​Neonates with high potassium levels and/or requiring large volumes transfusion
  • Patients who experience recurrent, severe allergic reactions
  • IgA deficient patients with anti-IgA antibodies or history of severe reaction to transfusions
  • Patients with a history of PTP, if HPA-matched donor red blood cells are unavailable


If you choose to print this information, it is valid only on date of print.

Laboratory Controlled Document LSM-795 v3

Last Modified: Friday, February 9, 2018 |
Questions or feedback about this page?